Depixus Overview
- Founded
-
2012
- Status
-
Private
- Employees
-
63
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$34.9M
- Investors
-
8
Depixus General Information
Description
Developer of a single molecule genetic and epigenetic sequencing technology intended to offer extraction of genetic and epigenetic information from single molecules of DNA and RNA. The company's SIMDEQ (SIngle-molecule Magnetic DEtection and Quantification) technology permits a full genome or genomic region to be analyzed quickly and easily on a single integrated platform, with the investigator to specify the level of sequence and epigenetic detail required, enabling doctors with simple sample-preparation, sequential DNA fingerprinting, full-sequencing and epityping to avail a fast time-to-result.
Contact Information
Website
www.depixus.com
Formerly Known As
PicoSeq
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Devices and Supplies
Other Healthcare Technology Systems
Primary Office
- 3-5 Impasse Reille
- 75014 Paris
- France
+33 09 00 00 00 00
Depixus Timeline
Depixus Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series A) | 15-Dec-2021 | $34.9M | 000.00 | 000.00 | Completed | Generating Revenue |
| 6. Grant | 01-May-2019 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 5. Grant | 00000 | 00.000 | Completed | Generating Revenue | ||
| 4. Later Stage VC | 31-Dec-2018 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 3. Later Stage VC | 29-Mar-2018 | 00.000 | 00.000 | 00.000 | Completed | Generating Revenue |
| 2. Seed Round | 04-Sep-2017 | $2.33M | $2.33M | 00.000 | Completed | Generating Revenue |
| 1. Accelerator/Incubator | 26-Nov-2013 | Completed | Generating Revenue |
Depixus Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
Depixus Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a single molecule genetic and epigenetic sequencing technology intended to offer extraction of genetic and
Drug Discovery
Paris, France
63
As of 2022
000.00
00.00
0000-00-00
00000000000
000.00
000000
oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
0000000000000
South San Francisco, CA
00
As of 0000
000.00
00.00
0000-00-00
0000000000 0
000.00
000 00
e eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui offici
0000000000 000000000
London, United Kingdom
000
As of 0000
000.00
00000000000
000.00
Add Comparison
Depixus Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Quantapore | Venture Capital-Backed | South San Francisco, CA | 00 | 000.00 | 0000000000 0 | 000.00 |
| 000 00000000000 | Venture Capital-Backed | London, United Kingdom | 000 | 000.00 | 00000000000 | 000.00 |
| 0000000 0000000000 | Venture Capital-Backed | San Diego, CA | 00 | 0000 | 00000 00000 | |
| 000000 00000000 00 | Formerly VC-backed | Oxford, United Kingdom | 000 | 00.000 | 00000000 | 00.000 |
| 000000 00000 | Corporate Backed or Acquired | Carlsbad, CA | 00 | 000000000000 |
Depixus Patents
Depixus Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3686642-A1 | Multichannel close-up imaging device | Withdrawn | 24-Jan-2019 | 0000000000 | 00 |
| EP-3914949-A1 | Multichannel close-up imaging device | Pending | 24-Jan-2019 | 0000000000 | |
| CA-3123151-A1 | Method of nucleic acid enrichment using site-specific nucleases followed by capture | Pending | 12-Dec-2018 | 0000000000 | |
| AU-2019398707-A1 | Method of nucleic acid enrichment using site-specific nucleases followed by capture | Pending | 12-Dec-2018 | 0000000000 | |
| EP-3837379-A1 | Method of nucleic acid enrichment using site-specific nucleases followed by capture | Pending | 12-Dec-2018 | C12Q1/6806 |
Depixus Executive Team (6)
Depixus Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| John Berriman | Self | Chairman | 000 0000 |
| Lachlan MacKinnon | Lansdowne Partners | Board Member | 000 0000 |
| Mark Chin | Arix Bioscience | Board Member | 000 0000 |
| Ronald Lindsay Ph.D | Self | Board Member | 000 0000 |
| Stephen Allen Ph.D | Depixus | Chief Business Officer & Board Member | 000 0000 |
Depixus Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Depixus Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Bpifrance | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 | |
| Casdin Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Lansdowne Partners | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Horizon 2020 SME Instrument | Government | 000 0000 | 000000 0 | ||
| Innovate UK | Government | 000 0000 | 000000 0 |